Screening for pharmaceutical transformation products formed in river sediment by combining ultrahigh performance liquid chromatography/high resolution mass spectrometry with a rapid data-processing method

Analytica Chimica Acta

Volumn 810, Issue , 2014, Pages 61-70

  Li, Zhe ^a   Maier, Michael P ^b   Radke, Michael ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

In silico data processing; Pharmaceuticals; Transformation products; Ultrahigh performance liquid chromatography high resolution mass spectrometry; Water sediment test

Indexed keywords

AMIDES; DATA HANDLING; DRUG PRODUCTS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; PHASE INTERFACES;

CARBAMAZEPINE 10 ,11 EPOXIDES; DATA PROCESSING METHODS; IN-SILICO; QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY; STRUCTURAL INFORMATION; TRANSFORMATION PATHWAYS; TRANSFORMATION PRODUCTS; ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHIES;

METADATA;

1 NAPHTHOL; 4 AMINO 6 CHLORO 1,3 BENZENEDISULFONAMIDE; BEZAFIBRATE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CHLOROTHIAZIDE; DICLOFENAC; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; METOPROLOL; PROPRANOLOL; SALUAMINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG TRANSFORMATION; MASS SPECTROMETRY; PRIORITY JOURNAL; RIVER; SEDIMENT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WATER ANALYSIS; WATER SAMPLING;

IN SILICO DATA PROCESSING; PHARMACEUTICALS; TRANSFORMATION PRODUCTS; ULTRAHIGH PERFORMANCE LIQUID CHROMATOGRAPHY/HIGH RESOLUTION MASS SPECTROMETRY; WATER/SEDIMENT TEST;

AUTOMATIC DATA PROCESSING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GEOLOGIC SEDIMENTS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; RIVERS; WATER POLLUTANTS, CHEMICAL;

EID: 84892486290     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2013.12.012     Document Type: Article

References (39)

1. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products in the environment: agents of subtle change?. Environmental Health Perspectives 1999, 107:907-938.
2. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36:357-393.
3. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicology Letters 2002, 131:5-17.
4. Kümmerer K. Pharmaceuticals in the environment. Annual Review of Environment and Resources 2010, 35:57-75.
5. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquatic Toxicology 2006, 76:122-159.
6. Mompelat S., Le Bot B., Thomas O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environment International 2009, 35:803-814.
7. Celiz M.D., Tso J., Aga D.S. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environmental Toxicology and Chemistry 2009, 28:2473-2484.
8. Escher B.I., Fenner K. Recent advances in environmental risk assessment of transformation products. Environmental Science & Technology 2011, 45:3835-3847.
9. Neuwoehner J., Zilberman T., Fenner K., Escher B.I. QSAR-analysis and mixture toxicity as diagnostic tools: influence of degradation on the toxicity and mode of action of diuron in algae and daphnids. Aquatic Toxicology 2010, 97:58-67.
10. Helbling D.E., Hollender J., Kohler H.P.E., Singer H., Fenner K. High-throughput identification of microbial transformation products of organic micropollutants. Environmental Science & Technology 2010, 44:6621-6627.
11. Diaz R., Ibanez M., Sancho J.V., Hernandez F. Target and non-target screening strategies for organic contaminants, residues and illicit substances in food, environmental and human biological samples by UHPLC-QTOF-MS. Analytical Methods 2012, 4:196-209.
12. Krauss M., Singer H., Hollender J. LC-high resolution MS in environmental analysis: from target screening to the identification of unknowns. Analytical and Bioanalytical Chemistry 2010, 397:943-951.
13. Gómez M.J., Gómez-Ramos M.M., Malato O., Mezcua M., Férnandez-Alba A.R. Rapid automated screening, identification and quantification of organic micro-contaminants and their main transformation products in wastewater and river waters using liquid chromatography-quadrupole-time-of-flight mass spectrometry with an accurate-mass database. Journal of Chromatography A 2010, 1217:7038-7054.
14. Gao J.F., Ellis L.B.M., Wackett L.P. The University of Minnesota Pathway Prediction System: multi-level prediction and visualization. Nucleic Acids Research 2011, 39:W406-W411.
15. Loos M., Ruff M., Singer H. enviMass Version 1.0 Target Screening Software 2011, Eawag Dübendorf, Swizerland.
16. Fenner K., Gao J., Kramer S., Ellis L., Wackett L. Data-driven extraction of relative reasoning rules to limit combinatorial explosion in biodegradation pathway prediction. Bioinformatics 2008, 24:2079-2085.
17. Lahti M., Oikari A. Microbial transformation of pharmaceuticals naproxen, bisoprolol, and diclofenac in aerobic and anaerobic environments. Archives of Environmental Contamination and Toxicology 2011, 61:202-210.
18. Quintana J.B., Weiss S., Reemtsma T. Pathway's and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor. Water Research 2005, 39:2654-2664.
19. Zhong D.F., Sun L., Liu L., Huang H.H. Microbial transformation of naproxen by Cunninghamella species. Acta Pharmacologica Sinica 2003, 24:442-447.
20. Batt A.L., Kostich M.S., Lazorchak J.M. Analysis of ecologically relevant pharmaceuticals in wastewater and surface water using selective solid-phase extraction and UPLC-MS/MS. Analytical Chemistry 2008, 80:5021-5030.
21. Löffler D., Römbke J., Meller M., Ternes T.A. Environmental fate of pharmaceuticals in water/sediment systems. Environmental Science & Technology 2005, 39:5209-5218.
22. Gröning J., Held C., Garten C., Claußnitzer U., Kaschabek S.R., Schlömann M. Transformation of diclofenac by the indigenous microflora of river sediments and identification of a major intermediate. Chemosphere 2007, 69:509-516.
23. Leemann T., Transon C., Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sciences 1993, 52:29-34.
24. Beyers H., Malan S.F., van der Watt J.G., de Villiers M.M. Structure-solubility relationship and thermal decomposition of furosemide. Drug Development and Industrial Pharmacy 2000, 26:1077-1083.
25. Della Greca M., Iesce M.R., Previtera L., Rubino M., Temussi F. A new photoproduct of the drug furosemide in aqueous media. Environmental Chemistry Letters 2004, 2:155-158.
26. Brigante M., DellaGreca M., Previtera L., Rubino M., Temussi F. Degradation of hydrochlorothiazide in water. Environmental Chemistry Letters 2005, 2:195-198.
27. Bedner M., Maccrehan W.A. Transformation of acetaminophen by chlorination produces the toxicants 1,4-benzoquinone and N-acetyl-p-benzoquinone imine. Environmental Science & Technology 2006, 40:516-522.
28. Buser H.R., Poiger T., Müller M.D. Occurrence and environmental behavior of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater. Environmental Science & Technology 1999, 33:2529-2535.
29. Zwiener C., Seeger S., Glauner T., Frimmel F.H. Metabolites from the biodegradation of pharmaceutical residues of ibuprofen in biofilm reactors and batch experiments. Analytical and Bioanalytical Chemistry 2002, 372:569-575.
30. Ferrando-Climent L., Collado N., Buttiglieri G., Gros M., Rodriguez-Roda I., Rodriguez-Mozaz S., Barceló D. Comprehensive study of ibuprofen and its metabolites in activated sludge batch experiments and aquatic environment. Science of the Total Environment 2012, 438:404-413.
31. Selke S., Hühnerfuss H. Detection and stereoselective analysis of three metoprolol metabolites in STP-effluent samples. Organohalogen Compounds 2009, 71:463-467.
32. Arterburn J.B. Selective oxidation of secondary alcohols. Tetrahedron 2001, 57:9765-9788.
33. Kern S., Baumgartner R., Helbling D.E., Hollender J., Singer H., Loos M.J., Schwarzenbach R.P., Fenner K. A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment. Journal of Environmental Monitoring 2010, 12:2100-2111.
34. Ramil M., El Aref T., Fink G., Scheurer M., Ternes T.A. Fate of beta blockers in aquatic-sediment systems: sorption and biotransformation. Environmental Science & Technology 2010, 44:962-970.
35. Uwai K., Tani M., Ohtake Y., Abe S., Maruko A., Chiba T., Hamaya Y., Ohkubo Y., Takeshita M. Photodegradation products of propranolol: the structures and pharmacological studies. Life Sciences 2005, 78:357-365.
36. Otey C.R., Bandara G., Lalonde J., Takahashi K., Arnold F.H. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnology and Bioengineering 2006, 93:494-499.
37. Valkó K. Retention prediction of pharmaceutical compounds. Journal of Chromatography Library 1995, 47-92. Elsevier, (Chapter 2). M.S. Roger (Ed.).
38. Schwarzenbach R.P., Gschwend P.M., Imboden D.M. Environmental Organic Chemistry 2003, John Wiley & Sons, Inc., Hoboken, NJ. 2nd ed.
39. Miao X.-S., Metcalfe C.D. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Analytical Chemistry 2003, 75:3731-3738.